MSI-H
2 drugsPredictive biomarker for patient selection in 17 indications
2
Approved Drugs
17
Indications
1
Companies
MSI-H is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 1 company, spanning 17 indications including Melanoma, Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma. Explore the targeted therapies, indications, testing methods, and companies developing MSI-H drugs below.
Search MSI-H Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting MSI-H
MSI-H Indications
Melanoma Non-Small Cell Lung Cancer Malignant Pleural Mesothelioma Renal Cell Carcinoma Classical Hodgkin Lymphoma Squamous Cell Carcinoma of the Head and Neck Urothelial Carcinoma Colorectal Cancer Hepatocellular Carcinoma Esophageal Cancer Gastroesophageal Junction Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Esophageal Adenocarcinoma Cutaneous Melanoma Microsatellite Instability-High Cancer Mismatch Repair Deficient Cancer